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Transferosomes, also known as transfersomes, are ultradeformable vesicles for 
transdermal applications consisting of a lipid bilayer with phospholipids and an edge 
activator and an ethanol/aqueous core. Depending on the lipophilicity of the active 
substance, it can be encapsulated within the core or amongst the lipid bilayer. Compared 
to liposomes, transferosomes are able to reach intact deeper regions of the skin after 
topical administration delivering higher concentrations of active substances making them 
a successful drug delivery carrier for transdermal applications. Most transferosomes 
contain phosphatidylcholine (C18) as it is the most abundant lipid component of the cell 
membrane, and hence, it is highly tolerated for the skin, decreasing the risk of undesirable 
effects, such as hypersensitive reactions. The most common edge activators are 
surfactants such as sodium deoxycholate, Tween® 80 and Span® 80. Their chain length is 
optimal for intercalation within the C18 phospholipid bilayer. A wide variety of drugs 
has been successfully encapsulated within transferosomes such as phytocompounds like 
sinomenine or apigenin for rheumatoid arthritis and leukaemia respectively, small 
hydrophobic drugs but also macromolecules like insulin. The main factors to develop 
optimal transferosomal formulations (with high drug loading and nanometric size) are  
the optimal ratio between the main components as well as the critical process parameters 
for their manufacture. Application of quality by design (QbD), specifically design of 
experiments (DoE), is crucial to understand the interplay among all these factors not only 
during the preparation at lab scale but also in the scale-up process. Clinical trials of a 
licensed topical ketoprofen transferosomal gel have shown promising results in the 
alleviation of symptons in orthreothritis with non-severe skin and subcutaneous tissue 
disorders. However, the product was withdrawn from the market which probably was 
related to the higher cost of the medicine linked to the expensive manufacturing process 
required in the production of transferosomes compared to other conventional gel 
formulations. This example brings out the need for a careful formulation design to exploit 
the best properties of this drug delivery system as well as the development of 
manufacturing processes easily scalable at industrial level.  
 
Key words: transferosomes, ultradeformable vesicles, transdermal administration, 
natural products, edge activator, quality by design (QbD)  
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1. Skin as a barrier for topical and transdermal therapies 
Skin is the largest interface between the human body and the external environment 
(Prausnitz et al., 2012). Being the body’s largest organ (Hadgraft and Lane, 2011), skin 
maintains body’s homeostasis by regulating the entrance and clearance of different 
substances, preventing excessive water loss and maintaining body temperature. However, 
exchange of substances across the skin is very limited as its primary function is protection 
compared to the gastrointestinal tract or the lung epithelial which are designed for 
compound exchange (Prausnitz et al., 2012).  
Skin is composed of three main layers: the epidermis (the outer layer), the dermis (the 
middle layer containing sensory receptors, sweat glands and various connective fibers) 
and the hypodermis (subcutaneous layer which contains adipose tissue and anchors the 
other two outer layers of the skin for support) (Hadgraft and Lane, 2011). The outermost 
layer of the skin, the “stratum corneum” (SC) which is made up of a broad 10-15 m size 
matrix of flattened, dehydrated and dead keratolytic cells (corneocytes), that are 
surrounded by an extracellular milieu of lipids organized as multiple lamellar bilayers, 
remains the main barrier to the topical or transdermal delivery (Rane and Gujarathi, 
2016). The structure of the SC is a composite material made of proteins and lipids 
structurally organized as “bricks and mortar” (Prausnitz et al., 2012; Rane and Gujarathi, 
2016) in which the corneocytes are envisaged as the bricks and the intercellular lipids and 
esters organized into lamellar membranes surrounding the corneocytes being the mortar 
that holds them together (Kleesz et al., 2012). The human SC is typically comprised of 
about 20 corneocyte cell layers with varying thickness, packing of keratin filaments, 
filaggrin content and a number of corneodesmosomes depending on the site. A highly 
cross-linked sheath surrounds corneocytes, while their cell interior is packed with keratin 
filaments embedded in a filaggrin matrix. The extracellular matrix comprises of 
structured lipids preventing excessive loss of water from the body and block the entry of 
most topically applied drugs, except those that are lipophilic (Log P: 1-3) and with low 
molecular weight (<500 Da) for which this extracellular, lipid-enriched matrix acts as a 
reservoir within which lipophilic drugs can accumulate and be slowly released (Prausnitz 
et al., 2012). Although corneocytes play a role as spacers and as a scaffold for the lipid-
enriched extracellular matrix, the latter has been the primary focus of transdermal 
delivery strategies.  
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Nanoparticulate delivery systems offer advantages in overcoming the SC as they have 
shown to enable the delivery and permeation of hydrophilic compounds and bio-
macromolecules to reach deeper layers of the skin, provide a sustained depot effect locally 
and increase transdermal delivery resulting in enhanced bioavailability. In particular, 
transferosomes are advantageous over other nanoparticulate drug delivery systems in the 
administration of drugs across the skin as their composition contains a greater amount of 
safe and biocompatible excipients (phospholipids, commonly soya lecithin) and have the 
capability of squeezing and permeate across the SC and deeper layers of the skin without 
losing their structure (Rajan et al., 2011). The differentiating effect will be discussed over 
the next sections. 
2. Transferosomes 
2.1. Transferosomes: versatile and flexible nano-vesicular carriers 
The word transferosome is a registered trademark by the German company IDEA AG 
and the name derives from the Latin word “transferre” meaning “to carry across” and the 
Greek word “soma” meaning “body”. The technology was first described in 1991 by Çevc 
and Blume and has been the subject of several patents and research over the last 30 years 
(Naik, 2013; Rai et al., 2017). Although there has been almost 30 years since the first 
time that the term transferosome has been used, this drug delivery system can still be 
considered novel as very few transferosomal formulations have been translated into 
clinical products. Similar trend has occurred with liposomes. The first report about 
liposomes in literature dates from 1970 (Sessa and Weissmann, 1970), being 
AmBisome®, one of the first liposomal formulations coming to the market in 1996 
(AEMPS, 2017). For this reason, it can be expected that more transferosomes will be 
commercialized in the following coming years. 
Transferosomes are lipid-based vesicular carriers that compared to the rigid lipid bilayers 
(liposomes) or non-ionic surfactant single layer vesicles (niosomes) are elastic, ultra-
deformable and stress-responsive (Rajan et al., 2011). When drug delivery systems, such 
as liposomes, nanoparticles and niosomes are deposited on the skin, usually they are only 
able to permeate through the upper layers of the SC, resulting in accumulation in the 
epidermal layer but failing to reach deeper areas of the skin such as the dermis or effective 
systemic levels. Liposomes are by far one of the most commonly used drug delivery 
system for skin purposes. However, the mechanism of liposomal permeation is still not 
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fully understood. Several authors support that small unilamellar liposomes have greater 
skin permeation capacity than larger ones (Verma et al., 2003). For example, liposomes 
with a 120 nm particle size reached to deeper skin areas (viable epidermis and dermis) in 
4.6-fold greater amounts than liposomes with 191 nm in size and 33-fold higher than 810 
nm liposomes (Verma et al., 2003). In addition, multilayered liposomes have been shown 
to be able to loose external layers during penetration facilitating the permeation of smaller 
vesicles with intermediate size (100-300 nm) leading to deeper drug penetration (Morrow 
et al., 2007). Hyaluronate chitosan multilayer liposomes (containing 10 alternating layers) 
with 528 nm particle size exhibited an enhanced transdermal delivery than uncoated 
unilamellar liposomes (~100 nm) (Jeon et al., 2015). Similarly, multilayered 
nanostructured lipid nanoparticles coated with hyaluronic acid and chitosan (181 nm) 
showed a two-fold larger flux across rat skin compared to uncoated nanoparticles (Zhang 
et al., 2016). In contrast, other authors support that multilamellar and small unilamellar 
liposomes possess similar ability to penetrate into the SC and viable skin 
(Lymberopoulos, 2017). Liposomes penetrate mainly into the SC but as much lesser 
extent in the epidermis and dermis (800 and 10,000 times less) (Lasch, 1992). Actually, 
more than size, their lipid composition plays a greater role in the skin permeation. 
Liposomal lipids can penetrate until 20 µm reaching the viable epidermis in greater 
amount than the whole liposomes per se (Peralta et al., 2018). Only liposomes containing 
dioleoylphophatidylethanolamine (DOPE) as lipid were able to penetrate into deeper 
stratum corneum (Lasch, 1992). Regarding niosomes, their penetration capacity has been 
associated with reduced fluxes across the SC compared to conventional liposomes even 
though are more stable and resistant to changes in osmolarity (Agarwal et al., 2001; Naik, 
2013; Rai et al., 2017; Rajan et al., 2011). In terms of zeta-potential, transferosomes seem 
have shown the greatest colloidal stability when compared to liposomes and niosomes in 
liquid media (van Zyl et al., 2019); transferosomes have exhibited good colloidal stability  
(with no sign of aggregation) up to three months both at 4 ⁰C and 25 ⁰C (Hadidi et al., 
2018), while niosomes and liposomes have shown poorer physical stability with greater 
tendency for aggregation at the same temperatures (Fathi-Azarbayjani et al., 2015). This 
fact can explain why most of the commercial liposomal formulations are marketed as 
freeze-dried powders in order to enhance the shelf-life of the product (AEMPS, 2017). 
Transferosomes are composed by four key elements: i) phospholipids (such as 
phosphatidylcholine, dipalmitylphosphatidylcholine, distearylphosphatidylcholine), ii) 
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an edge activator such as a surfactant or bile salt ranging from 10-25% (e.g. sodium 
cholate, sodium deoxycholate, Tween® 80, Span® 80, dipotassium glycyrrhizinate), iii) 
ethanol in a lower percentage usually below 10 % (as higher concentrations are described 
as ethosomes) and iv) water as a vehicle (Fig. 1) (Rai et al, 2017; Rajan et al, 2011; 
Morrow et al, 2007). Transferosomes are highly ultra-deformable and are able to squeeze 
through the SC and penetrate as intact vesicles through the skin when their size is below 
300 nm and when they are applied under non-occlusive conditions that maintains the 
trans-epidermal osmotic gradient which acts as the driving force for the elastic transport 
into the skin (Naik, 2013; Rai et al., 2017; Rane and Gujarathi, 2016).  
In this respect, the edge activator plays a key role as it provides a high radius of curvature 
that can destabilize the lipid bilayer increasing the deformability of the membrane. This  
allows transferosomes to spontaneously squeeze though channels in the SC that are less 
than one-tenth the diameter of the vesicles and prevents vesicle rupture when crossing 
through the different skin layers (Naik, 2013; Rane and Gujarathi, 2016). The 
concentration of the edge activator in the formulation (usually between 10-20 %) is 
crucial and ideally included in sub-lytic concentrations i.e. not able to cause destruction 
of vesicles (Naik, 2013; Rai et al., 2017; Rajan et al., 2011). The risk of formation of 
mixed micelles increases when amounts of edge activator greater than 15 % are used 
(Jangdey et al., 2017). 
Hydrophilic drugs are encapsulated within the aqueous central cavity, while more 
hydrophobic drugs are embedded within the phospholipid bilayer. Transferosomes are 
typically below 300 nm being more elastic and flexible than liposomes (typically five-
eight times higher), which makes them highly suitable for skin penetration (Rai et al., 
2017; Rane and Gujarathi, 2016), although higher sizes can be obtained due to the 
aggregation of the particles. An optimal zeta-potential in transferosomes is lower than -
30 mV or higher than +30 mV in order to ensure colloidal stability; otherwise the risk of 
aggregation increases significantly (Hanaor et al., 2012). 
2.2. Mechanism of transferosome penetration across the SC 
As these novel artificial carriers are self-adaptable, they can go through pores much 
smaller than their own size by changing their shape and size easily and rapidly, by 
adjusting lipid bilayer components to the surrounding stress experienced by the system, 
and thus being able to carry drugs with a high molecular weight across the intact skin 
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(Fig. 2). As these molecules with a high molecular weight are barely able to reach the 
deepest layers of the skin and the bloodstream, transferosomes are an alternative to 
subcutaneous administration of insulin or IFN-α, showing a 50 % of response when 
compared with insulin and sufficient concentration of IFN-α for immunotherapy (Reddy, 
2015). When transferosomes are administered on the surface of the skin, they are able to 
permeate across the different layers of the skin by going through the intercellular lipids 
as well as lipid cell membranes (Rai et al., 2017; Rane and Gujarathi, 2016). The skin 
penetration of these vesicles lies on the interdependency of the local composition and 
shape of the bilayer which makes the vesicle both self-regulating and self-optimizing 
enabling the transferosomes to cross various transport barriers efficiently and then acting 
as a drug carrier for non-invasive targeted drug delivery and sustained release of 
therapeutic agents (Rai et al., 2017; Rajan et al., 2011; Rane and Gujarathi, 2016).  
The penetration of intact transferosomes through the SC occurs due to the “transdermal 
osmotic gradient” caused by the difference in water content between the relatively 
dehydrated skin surface (approximately 15 % water) and the aqueous viable epidermis 
(close to 75 %) (Rajan et al., 2011). This difference in hydration is a physiological feature 
of the skin in order to prevent water loss. Based on the principles of elastomechanics, the 
hydrophilic lipid vesicles establish an energetically favorable interaction, which force 
them to escape from the complete drying environment moving them to more hydrated 
regions (Naik, 2013; Rai et al., 2017; Rajan et al., 2011). Hence, transferosomes are 
subject to evaporation and in order to avoid dehydration, the vesicles deform, penetrate 
across the SC, and travel towards deeper and more aqueous areas of the skin to rehydrate 
(Rai et al., 2017). Transferosomes have the ability to modify their shape, but the internal 
entrapped volume capacity does not change drastically and therefore the solubility of the 
entrapped drug in the core should not be altered significantly. Small breakages could 
occur in the lipid bilayer due to the deformation during the penetration across the skin 
resulting in the partial release of ethanol/water content from the core. However, this 
situation is reverted during the rehydration process with water from the viable epidermis. 
The flexibility of the transferosomal membrane decreases the risk of complete vesicle 
rupture in the skin and allows the transferosomes to change their membrane composition 
locally and reversibly, while passing through the intercellular gaps and intracellular lipid 
cell membranes. This self-optimizing deformability allows the transferosomes to 
dehydrate and deform to cross through small gaps while they can recover their shape by 
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a rehydration process (Naik, 2013; Rai et al., 2017; Rajan et al., 2011). Actually, these 
rheological and hydration properties responsible for their great deformability are 
attributed to the combination of the phospholipids and edge activator in an optimal ratio 
(Rajan et al., 2011). 
Previous research suggested that the penetration of the formulation through the skin is 
forced by a osmotic gradient that is caused by the different water content between the 
relatively dehydrated skin surface (with a ≈20 % of water) and the aqueous viable 
epidermis (≈75 % water content). A lipid formulation applied in the surface of the skin 
avoids evaporation and, consecuently, dehydration, allowing transferosomes to reach 
deeper layers of the skin (Benson, 2006). In the case of PEGylated transferosomes 
containing terpenes as edge activators, apart from the good elastic characteristics of the 
transferosomes, a greater in vitro/in vivo performance has been associated with the fact 
that terpenes-containing vesicle bilayers could enter the SC by altering the intercellular 
lipids lamellar and also by the effect of PEG that could hydrate the skin facilitating the 
transport based on the hydration gradient (Wang et al., 2017).  
A sustained drug release can occur from transferosomal formulations. It has been reported 
a burst effect from transferosomes during the first 4 hours upon administration followed 
by a slow release afterwards. Considering that hydrophilic drugs are located in the core 
of the transferosome, their release would be slower compared to hydrophobic drugs, 
which are located in the lipid bilayer. However, the burst effect observed during the first 
hours upon administration has been also linked with a small breakage of the lipid bilayer 
due to the vesicle deformation taking place during the permeation, allowing a partial 
release of the drug located in the core (Omar et al., 2019). PEG-coating in the surface of 
the transferosome has also lead to sustained drug release during prolonged periods of time 
(Panwar et al., 2010). 
3. Transferosomes in preclinical studies - Laboratory scale preparation 
The thin film hydration technique is the most widely strategy to prepare transferosomes 
at lab-scale (Table 1). The main advantages of this technique when a suitable ratio 
between lipid:edge activator:drug is selected are that nanometric particle size, high 
entrapment efficiency and high yield can be easily obtained. The thin film hydration 
technique is the most common method at lab scale, due to the simplicity of the technique 
and the short time required to prepare the formulation. However, this technique has 
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several limitations including poor scalability mainly related to the fact that the particle 
size of the formulation is highly dependent on the volume capacity of the equipment 
employed and the energy applied in the process (Kraft et al., 2014). The desired features 
of the transferosomes can be easily altered during the scaling-up of this method (Paliwal 
et al., 2014). For example, it was proven that the particle size was reduced when greater 
impeller speed and agitation times were used (Colombo et al., 2001). In addition, this 
bottom-up approach is less popular in industry as it requires removal of the traces of the 
remaining solvent (Junghanns and Muller, 2008). Other disadvantage associated with this 
technique is that often requires a downsizing technique to make the transferosomes more 
uniform and within the nanometric range (Wagner and Vorauer-Uhl, 2011). The scale-up 
of this downsizing step is challenging at industrial level.  
Most transferosomes contain phosphatidylcholine (C18) as the lipid fraction (usually 
above 70%) as it is the most abundant lipid component of the cell membrane, and hence, 
it is highly tolerated for the skin, decreasing the risk of undesirable effects, such as 
hypersensitivity reactions (Ishikawa et al., 2017). Soya phosphatidylcholine (>95 % 
purity) is a GRAS (Generally Regarded As Safe) excipient and actually it has been used 
in suspensions, emulsions, mixed micelles, solid dispersions and drug-phospholipid 
complexes with a good safety profile (Rajan et al., 2011; van Hoogevest and Wendel, 
2014).  
The most common edge activators employed are sodium deoxycholate, Tween® 80 
(polyoxyethylene 20 sorbitan monooleate) and Span® 80 (sorbitan monooleate) as their 
chain length is easier to intercalate within the C18 phospholipid bilayer (El Maghraby et 
al., 2004). There is a certain discrepancy amongst the results collected from the different 
studies included in Table 1. For this reason, a multilinear regression analysis was 
performed in order to evaluate the correlation between the percentage of lipids and edge 
activator in each formulation and the particle size, zeta-potential and permeability (Fig. 
3). Formulations containing an ionic edge activator, such as sodium deoxycholate, were 
analysed separated from those formulated with non ionic surfactant such as Tween® 80 
or Span® 80. Overall, the general trend indicated that higher percentage of sodium 
deoxycholate led to lower particle size while large amounts of non ionic surfactants 
resulted in an increase in particle size. This is probably related with the volume of the 
polar head of the non ionic surfactants and with the greater intercalation of the sodium 
deoxycholate within the lipid bilayer leading to an increase in the curvature of the 
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transferosomes. Regarding the in vitro permeability, there was a positive correlation 
between the amount of sodium deoxycholate and the permeability across the skin. 
Opposite effect was observed for those transferosomes containing non ionic edge 
activators which can be related to the larger particle size obtained with larger amounts of 
this type of surfactant. 
The percentage of edge activator ranges from 4 % till 20 % (Table 1). Overall, drug 
entrapment is improved when higher concentrations of edge activator are employed  
(usually up to 10 %). However, a ratio above 10 %, in the case of valsartan 
transferosomes,  led to lower drug encapsulation (from 93.56 to 62.73 %) because the 
lipid bilayer of the transferosome becomes disrupted and more leaky releasing the 
entrapped drug (Ahad et al., 2012b). Also mixed micelles can co-exist with 
transferosomes when the surfactant exceeds 15 % of the total composition, resulting in 
partial drug encapsulation within small size micelles and hence, lower drug entrapment 
within the transferosomes (Jangdey et al., 2017).  Larger entrapment values were obtained 
when Span® 80 was used as edge activator (1.5-fold higher entrapment efficiency than 
using sodium deoxycholate), while transferosomes including sodium deoxycholate have 
resulted in better permeation across the SC (16.8 versus 9-fold greater permeability) 
(Ahad et al., 2017). Better in vitro skin permeation and in vivo PK cutaneous permeability 
in microdialysis studies than conventional liposomes has been reported when 
monoterpenes such as limonene and citrol have been incorporated as edge activators 
(Wang et al., 2017). Also, the combination of phosphatidylcholine with DSPE-PEG2000 
has resulted in an increase in the transdermal permeation of the transferosomes (Wang et 
al., 2017).  
Span® 80 have been shown to act as a destabilizing agent and leads to highly deformable 
vesicles with enhanced permeation (Pathak et al., 2016). The hydrophilic-lipophilic 
balance (HLB) of the surfactant has an effect on particle size. The lower the HLB, the 
larger the particle size (Ahmed, 2015). The hydration medium temperature has also some 
influence in the final particle size. More stable smaller vesicles were obtained at 
temperatures around 20 ºC (Ahmed, 2015). 
Drugs with different physicochemical characteristics have been successfully entrapped in 
transferosomes ranging from small molecular weight hydrophobic drugs and 
phytocompounds (such as sinomenine or apigenine for rheumatoid arthritis and 
11 
 
leukaemia) to labile biomacromolecules such as insulin (>5 kDa) (Table 1). Drug loading 
can be tuned easily being able to encapsulate potent drugs at low doses such as tretinoin 
at 0.05 % but also high drug loading up to 20-25 % like  in the case of sinomenine. 
However, drug loading above 20 % is challenging considering the amounts of lipid and 
edge activator needed to produce stable transferosomes. Thus, entrapment of potent drugs 




4. Optimising transferosomal formulations using quality by design (QbD)  
The concept of QbD is usually used in pharmaceutical development and manufacturing 
to enhance the quality of the obtained products (Adam et al., 2011). QbD is a systematic 
approach that starts with predefined objectives (also known as “Target Product Profile” 
or product specifications) and emphasizes on product critical quality attributes (CQAs), 
understanding of critical process parameters (CPPs) and process control (Fig. 4). This can 
be improved by building quality standards into the process of development and 
manufacturing and not only testing the product at the end of the process (Defeo, 2016; 
Rathore and Winkle, 2009).  
This concept was introduced in the 2000s by the pharmaceutical industry combined with 
support from the Food and Drug Administration (FDA). Even though, the quality of the 
final products was usually ensured, a high percentage of the production was wasted 
because the quality control only took place at the end of the process, leading to higher 
costs associated with medicine manufacturing. Taking into account the high cost and 
complex production associated with nanomedicines, the optimisation of the 
manufacturing process is key to ensure that advance formulations, such as 
transferosomes, reach the market.  
According to the 21st Century Initiative, more controls were necessary to be implemented 
in manufacturing in order to improve efficiency and safety in the process leading to the 
establishment of GMP (Good Manufacturing Practices) (Rathore and Winkle, 2009). 
Since the FDA-GMP Initiative, new documents have been published by the International 
Conference on Harmonization (ICH) focused on the concept and implementation of QbD 
in pharma companies: Q8 Pharmaceutical Development, Q9 Quality Risk Management 
and Q10 Quality Systems Approach to Pharmaceutical GMP Regulations (Rathore and 
Winkle, 2009).  
In pharmaceutical R&D (research and development), QbD, specifically design of 
experiments (DoE), is commonly used to obtain optimised formulations taking into 
consideration a wide range of factors that can affect the Target Product Profile, as 
experiments are set up in an efficient and precise way (Savic et al., 2012). Formulation 
optimisation usually takes place in several steps, starting with a pre-screening design (also 
known as ruggedness testing) (Chen et al., 2017; Zhao et al., 2017) in order to identify 
the critical main factors of the process (Yang et al., 2014) utilising the minimum number 
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of experimental runs to be performed to ensure cost and time efficiency. Pre-screening is 
performed by using different types of factorial models, among which Plackett-Burman 
(Zhao et al., 2017) and Taguchi (Chen et al., 2017) are the most utilised. These models 
are useful to determine which factors have higher or lower, positive or negative influence 
in the development of the formulation (eg. amount of components or parameters in the 
manufacturing process). Once, the most influential factors have been identified with the 
pre-screening designs, response surface models are commonly employed to find the 
optimal design space. Mixture design spaces are also utilised where the suitable ratio 
between excipients needs to be identified but there is no investigation on the process 
parameters. 
Plackett-Burman design can appraise between 2 to 47 factors, where each factor is set to 
2 levels (higher and lower). This design can be applied to investigate up to N-1 variables 
with N experiments (Zhao et al., 2017). This design is particularly useful to test 
ruggedness when the aim is focused on finding a small or non-existent effect due to the 
factors (Zhao et al., 2017). A ruggedness test determines the sensitivity of a protocol to 
small changes in operational factors (Parker et al., 2014). The Taguchi model is an 
orthogonal array design which evaluates two-level factorial designs (higher and lower) 
(Chen et al., 2017). This type of DoE reduces effectively the number of experiments 
required in a design process, instead of having to test all possible combinations: the model 
only tests pairs of combinations (Chen et al., 2017; Rao et al., 2008). Taguchi focuses on 
the concept of robust design methodology where variations due to noise factors beyond 
the control of the design are considered and the obtained responses are only affected by 
controllable factors (Rao et al., 2008).  
Response surface methodology consists on a group of mathematical and statistical 
techniques based on the fit of empirical models to the experimental data obtained in 
relation to DoE (Bezerra et al., 2008). As an advance DoE technique designed to aid the 
better understanding and optimisation of the responses, it is often used to refine models 
once the major factors have been previously identified with a pre-screening test (Bezerra 
et al., 2008). There are two main types of response surface designs: the central composite 
and the Box-Behnken. A central composite design is a 2-full-factorial design that includes 
both the central and star points allowing estimation of curvature. The number of central 
points runs the design and the star points represent the extreme values (low and high) for 
each factor in the design. This design estimates efficiently first- and second-order terms 
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and is especially useful in sequential experiments as previous factorial experimental data 
can be fed in the design. In contrast, Box-Behnken design requires fewer design points 
and hence is less expensive to run with the same number of factors, however, lacks the 
ability to incorporate data from previous experiments. Additionally, Box-Behnken design 
always have three levels per factor unlike central composites which can have up to five 
(Ferreira et al., 2007; Khajeh, 2009). 
As a starting point in optimising transferosomal formulations, a mixture design can be 
applied taking into account that the suitable ratio among phospholipids, edge activator 
and drug should be identified utilising ternary diagrams (Fig 5A). The measured 
responses which are usually drug loading and particle size are assumed to depend only 
on the relative proportions of the excipients. Usually a fitting standard model is employed 
like Simplex-Lattice or Simplex-Centroid design, where the components must sum to one 
(or 100 %). However, they are usually combined with constrained mixture designs such 
as Extreme-Vertices design to introduce and define additional constrains such as the 
maximum and/or minimum value for each component. In the case of transferosomes, the 
amount of lipids needs to be always higher than the amount of edge activator to ensure 
formation of bilayered vesicles (Fig 5B-C) (Rispoli and Shah, 2008).  
5. Lab scale manufacture of QbD optimized transferosomes  
QbD has been employed in several studies towards preclinical development of 
transferosomal formulations (Table 2) (Csanyi, 2018; Gilani, 2019). The first example 
was the development of zolmitriptan transferosomes for migraine using 
phosphatidylcholine and Tween® 80. The effect of the amount of phospholipid, drug and 
edge activator on particle size, drug release and flexibility index (parameter that 
determines the deformability capacity of the transferosome across membranes) was 
evaluated using a Box-Behnken design (Pitta et al., 2017). The flexibility index was 
determined by extruding the formulation through a 0.22 µm filter assembled to a 
measuring cylinder and a vacuum pump. In order to determine the flexibility index, the 
particle size of the formulation was measured before and after passing through the filter 
for 15 min. In this case, a mixture design would have been more suitable as no process 
variables were investigated. Transferosomes were prepared using the rotary film 
evaporation method. Optimized transferosomes with a particle size below 100 nm, a 
flexibility index of 20.25 % and a drug release of 97 % after 10 h were prepared as 
followed: 38.79 % of soya lecithin (dissolved in chloroform) was added to 15.1 % of 
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Tween® 80 (dissolved in a methanol:chloroform (1:2) mixture) that was rota-evaporated 
at 68 °C to obtain a dry lipid film. The films were stored in a vacuum oven to eliminate 
traces of organic solvents prior reconstitution with the dissolved zolmitriptan (9.8 %) in 
pH 6 buffer under stirring for 1 h at 90 ⁰C at 60 rpm. After hydration of the film, the final 
formulation was annealed at room temperature for 2 hours, probe sonicated for 25 min 
with a pulse of 10 min and filtered through a 0.22 µm nylon filter (Pitta et al., 2017). An 
initial particle size of 93.3 nm was obtained after lyophilization, particles were 
agglomerated and size was increased above 1 µm. This formulation was developed for 
intranasal administration due to the high permeability of the nasal epithelium and the 
quick absorption by this route; brain delivery was possible through the olfactory pathway. 
An in vitro release study of the optimized transferosomal formulation was performed 
exhibiting a 97 % release after 10 h while the marketed nasal spray Zolmist® resulted in 
a 98 % release in 4 h. The bioavailability of the transferosomal formulation was found to 
be 1.72-fold higher than Zolmist®. 
Similary, a Box-Behnken design was employed in optimising raloxifene transferosomes 
for estrogen replacement therapy but utilising sodium deoxycholate as the edge activator. 
The investigated variables were the amount of phosphatidylcholine (100, 200 and 300 
mg) and edge activator (15, 35 and 55 mg) along with the probe sonication time (15, 25 
and 35 min, 325 W). The effect of these factors on the following three responses, 
entrapment efficiency, particle size and transdermal flux was investigated. The optimised 
formulation was prepared using the film evaporation method by dissolving the lipids 
(89.23 %), the raloxifene (0.36 %) and the edge activator (10.41 %) in a mixture of 
methanol and chloroform (1:2) and rota-evaporating the solvent mixture under vacuum 
at 40 °C until a dry lipid film was obtained. Overnight evaporation under vacuum to 
ensure no traces of solvents was necessary. Film rehydration using a PBS buffer (pH 6.5) 
by stirring for 1 h at 41-44 ⁰C at 120 rpm was performed. Transferosomes were annealed 
for 2-3 hours at room temperature, followed by probe sonication for 20-30 min (325 W) 
and extrusion through 0.45 and 0.22 µm polycarbonate membranes (Mahmood et al., 
2014). The optimised transferosomes possessed a particle size of 134 ± 9 nm, with a drug 
entrapment of 91 ± 4.9 % and exhibited a transdermal flux of 6.5 ± 1.1 µg/cm2/h. 
Transferosomal permeation was 1.05 and 4-fold higher than ethosomal raloxifene (6.194 
µg/cm2/h) and plain drug solution (1.6 µg/cm2/h), respectively (Thakkar et al., 2016). 
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A Box-Behnken design was also utilised in the optimization of valsartan transferosomes 
for hypertension employing sodium deoxycholate (DC) as edge activator. The effect of 
four variables on the drug encapsulation efficiency, permeation flux across the skin and 
particle size was investigated. The four variables were the following: i) amount of 
phosphatidylcholine (Phospholipon 90G at 75, 85 or 95 mg), ii) amount of edge activator 
(5, 15 and 25 mg), iii) amount of drug (40, 60 and 80 mg) and iv) sonication time (15, 25 
and 35 min). The optimised formulation was prepared using a similar film evaporation 
method as described above. Upon “trading off” response variables, the final formulation 
composition contained phosphatidylcholine (85 mg), DC (15 mg), valsartan (60 mg), 
using a sonication time of 25 minutes. The particle size was 130 ± 10 nm  with a 
encapsulation entrapment of 85.77 % ± 2.97 % and a transdermal flux across rat skin of 
627.47 ± 30.45 μg/cm2/h. Results of in vivo antihypertensive activity indicated that the 
transferosomal formulation  released the drug gradually over a period of time of 48 h, 
which resulted in prolonged control of hypertension, 3.6-fold times greater than liposomal 
valsartan (Ahad et al., 2012b). 
Sildenafil transferosomes were developed using a Plackett-Burman pre-screening design, 
allowing the investigation of the effect of a large number of factors with minimal number 
of experimental runs to elucidate which parameters were critical in the final 
characteristics of the transferosomes. Six variables on two different responses (particle 
size and entrapment efficiency) were investigated: i) drug:phospholipid molar ratio (1:2, 
1:6 or 1:10); ii) phospholipid:edge activator ratio (95:5, 85:15 or 72:25); iii) edge 
activators with different HLB (Tween® 80 or Span® 80); iv) pH of the PBS rehydration 
buffer (5.5, 6.5 or 7.5); v) hydration time (30, 75 or 120 min) and vi) temperature during 
hydration (2, 11 or 20 ºC). Drug, phospholipids and edge activator were dissolved in 
methanol and the solvent was evaporated in a rotatory evaporator under vacuum at 45 ⁰C 
until the lipid film was obtained. The flask was kept under vacuum overnight to ensure 
the complete solvent evaporation, prior rehydration with PBS of various pH over a range 
of times at different temperatures as described above. Finally, the formulation was bath 
sonicated for 30 minutes (Ahmed, 2015).  
Surfactant HLB and temperature of the hydration medium had a positive effect on the 
vesicle size of the transferosomes, and hence, a decrease in the HLB led to an increase in 
particle size probably due to the affinity between edge activator and lipids. A higher 
temperature of the medium led to the formation of more stable smaller vesicles. Factors 
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with a significant impact on entrapment efficacy were the drug:phospholipid ratio and the 
pH of the hydration medium. Increase in the entrapment efficacy was obtained using 
lower amount of lipids, which was atributed to the competition between the drug and the 
lipid in the bilayer of the transferosomes, which led to an exclusion of the drug inside the 
vesicle. As the drug’s solubility decreased with increasing the pH of the hydration 
medium, a higher entrapment was obtained at higher pH due to a migration of the drug 
into the transferosomes cavity and lamellar layers (Ahmed, 2015). The in vitro 
permeation study showed that the optimized formulation had a 5-fold higher permeation 
compared with sildenafil suspension. The release profile of the transferosomal 
formulation was biphasic, with a burst release in the first 4 hours followed by a sustained 
release. This could be explained by the fact that a fraction of the drug was located on the 
surface of the transferosome which is rapidly released, while the encapsulated fraction 
within the transferosome followed a sustained release.   
Apigenin transferosomes were optimised using a 3-level 3-factors Box-Behnken design. 
Phospholipid/edge activator ratio (85:15, 90:10, 95:5), sonication time (10, 20, 30 min) 
and rotation speed (20, 40, 60 rpm) were the investigated factors, while particle size, drug 
loading and entrapment efficacy were the chosen responses. Phosphatidylcholine, 
Tween® 80 and apigenin were dissolved in ethanol, which was later evaporated by rotary 
evaporation to form the lipid film in the flask. The film was hydrated at 45 °C using PBS 
and a speed rotation of 60 rpm. The transferosomes were annelled at room temperature 
for 2 hours followed by probe sonication to reduce particle size. Drug retention in the 
skin after 24 h was 1.4-fold and 1.1-fold higher than the drug suspension and the marketed 
product (Jangdey et al., 2017), respectively. 
Timolol transferosomes were optimised using a 23 full factorial design (8 experimental 
runs). Two parallel designs were carried out using two different carriers either spray-dried 
lactose or mannitol. Phosphospholipid/edge activator ratio (3:1, 9:1), carrier/solvent 
mixture ratio (5:1, 20:1) and edge activator type (Span® 80, Tween® 80) were the 
selected factors, while particle size, entrapment efficacy and release rate were the chosen 
responses. Phosphatidylcholine, edge activator and timolol were dissolved in a 2:1 
mixture of chloroform:methanol (v/v). Later, the carrier (spray-dried lactose or mannitol) 
was added and the mixture was rota-evaporated for 30 min at 55 °C under reduced 
pressure. The resultant powder was kept in a dessicator overnight at room temperature to 
remove all traces of organic solvents. The optimised formulation containing spray-dried 
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lactose showed a greater permeation (1.3-fold) after 24 h than the one containing mannitol 
(Morsi et al., 2017). 
A 23 full factorial design was also utilised for the development of optimised miconazole 
nitrate transferosomes entrapped in a Carpobol 934 gel for the treatment of candidiasis. 
Type of surfactant, total amount of lipids and phospholipid/surfactant ratio were the 
independent factors. The optimised formulation was consisted of soya lecithin and Span® 
80 (ratio 90:10 w/w) and was loaded with clinical relevant amounts of miconazole (23.08 
%). Treatment of Candida albicans infected rats with commercially available Daktarin® 
cream (2 %) allowed for reduction of the oedema and signs of inflammation; however, 
scarring was still present. In contrast, the transferosomal gel showed similar efficacy but 
with fewer signs of acanthosis (Qushawy et al., 2018).  
Paclitaxel transferosomes were optimised using a 3-level 3-factors Box-Behnken design 
(15 experimental runs). The amounts of soya lecithin, cholesterol and Span® 80 were the 
selected factors, while entrapment efficiency, particle size and cumulative drug 
permeation were the investigated responses. Soya lecithin, paclitaxel and cholesterol 
were dissolved in a mixture of ethanol and chloroform, followed by the addition of Span® 
80. This mixture was probe sonicated for 30 min and later evaporated to dryness in a 
water bath at 60 ºC. The resulting film was hydrated with 200 ml of phosphate buffer pH 
6.8 (Pathak et al., 2016). The gel formulation of paclitaxel encapsulated within 
transferosomes showed a 3.4-fold higher permeation than the control gel (freely dispersed 
paclitaxel in carbopol gel matrix) after 24 h. 
Insulin transferosomes were optimised using a 23 full factorial design (8 experimental 
runs). Phosphatidylcholine/cholesterol ratio (8:3, 10:1 w:w), lipids/edge activator ratio 
(1:1, 1.47:1 w:w) and Tween® 80/sodium deoxycholate ratio (4:6, 7:3 w:w) were the 
selected factors. Phosphatidylcholine, cholesterol and Tween® 80 were placed inside a 
flask and dissolved in a mixture of diethyl ether:chloroform (3:1 v:v). The flask was kept 
at room temperature for 24 h until the film was formed. Insuline solution (1.4 mg/ml in 
water) was added to the flask and probe sonicated (20 KHz, 2 min). After that, the film 
was hydrated using sodium deoxycholate in PBS pH 7.4 and sonicated for 2 min. 
Dimethyl sulfoxide (2 % v/v) was added as chemical permeation enhancer and later 
passed through Watman® filter paper (Nº. 40). The transferosomal suspension was 
transferred to 5 % w/v methylcellulose gel (Malakar et al., 2012). Optimised formulation 
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had a 1.3-fold higher permeation through porcine ear skin when applied in the presence 
of iontophoresis. 
A 34 design was utilised to optimise resveratrol transferosomes entrapped into a Carbopol 
934-Poloxamer 407 gel for intranasal administration in the treatment of Alzheimer’s 
disease. The following independent factors were studied: phosphatidyl 
choline/permeation enhancer excipient ratio (7:3, 8:2, 9:1, w:w), (Phosphatidyl 
choline+permeation enhancer excipient)/edge activator ratio (2:1, 3:1, 4:1, w:w), type of 
edge activator (Tween® 80, sodium deoxycholate or Cremophor® RH 40) and type of 
permeation enhancer excipient (Transcutol®, oleic acid or ethanol). Particle size, 
polydispersity index, zeta-potential and entrapment efficiency were the selected 
responses. Resveratrol (10 mg), edge activator and phosphatidylcholine were dissolved 
in a 2:1 (v:v) chloroform:methanol mixture, vortexed for 10 min and later evaporated in 
a diseccator for 24 hours. The film was then hydrated with nasal simulated fluid (10 ml) 
at pH 5.5 which contained the permeation enhancer. The vesicles were formed and then 
annelled for 2 hours at room temperature. The mixture was then probe sonicated (20 min) 
and extruded through a 0.22 µm filter to reduce particle size. The transferosomal 
suspension was centrifuged (3 h, 20000 rpm, 4 ⁰C) to be separated and then reconstituded 
with nasal simulated fluid. The transferosomal gel was formed by adding Carbopol 934 
and then Poloxamer 407 to the reconstituted transferosomes. The mixture was stirred until 
a clear solution was obtained. Two drops of triethanolamine were finally added to adjust 
the pH and form the gel. Optimised transferosomes resulted in 4.5-fold more permeable 
than resveratrol suspension across sheep nasal mucosa (Salem et al., 2019). 
Overall, it can be concluded that pre-screening fractional designs such as Plackett-
Burman or Taguchi are useful DoE at the first stages during the development of a novel 
transferosomal formulation in order to understand what are the key parameters affecting 
the particle size, drug loading and release. However, full factorial designs and specifically 
those including 3-levels and 3-factors are more interesting when the key factors are 
already known and a detail optimisation is carried out. It is worthy nothing that at lab-
scale, the Critical Material Attributes (CMAs) such as amount of lipids, drug and edge 
activator play a more relevant role on the Critical Quality Attributes (CQAs) of the 
transferosomal formulation (mainly particle size and drug entrapment). However, Critical 
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Process Parameters (CPPs) such as reconstitution volume, stirring and sonication time 




6. Scale-up: from bench to industrial manufacturing  
The film evaporation method is the classical strategy to produce transferosomes at lab 
scale (Ahmed, 2015; Mahmood et al., 2014; Pitta et al., 2017). Experience in utilising this 
technique for industrial scale-up of liposomes and ethosomes is challenging and hampers 
the clinical traslation from bench to market of these nanomedicines. The main reason is 
the need for small batch sizes which increases manufacturing costs as well as the time 
needed to produce necessary quantities of the optimal formulation (Wagner and Vorauer-
Uhl, 2011). Several techniques have been implemented in industry to obtain 
transferosomes at a larger scale based on lessons learned on liposomal industrial 
manufacturing (Table 3 & Fig. 6). 
In homogenization/extrusion techniques, rehydrated films are subjected to constant 
pressure changes to break down multilaminar vesicles instead of sonication prior to the 
mixture is passed through different orifices to obtain transferosomes of different sizes 
(Wagner and Vorauer-Uhl, 2011). This method is easy to scale-up and the reduction of 
particle size remains reproducible; however, the process is time and resource consuming. 
The ethanol injection method is based on the addition of ethanol into the aqueous phase. 
By that, the lipid molecules precipitate and form bilayer planar fragments, which 
themselves form lipid vesicles and entrap the aqueous media. This method is easy to 
scale-up, just by increasing the volume of the vessels and usually allows to obtain vesicles 
with higher entrapment efficacy and higher stability. The particle size can be tunned by 
controlling the ratio between lipids and edge activator and also by adjusting the whole 
diameter of the injection tool, the pressure of injection and the flow rate of the aqueous 
phase (Wagner and Vorauer-Uhl, 2011). 
Protransferosome-transferosome method consists of the preparation of in situ 
transferosomes. The transferosome can be prepared using the same lab scale methods 
above mentioned (Davidson et al., 2016). The transition from a protransferosome to a 
transferosome takes place by diluting the formulation using an aqueous phase (Wagner 
and Vorauer-Uhl, 2011). This method is easy to scale-up and the stability of the 
formulation is usually acceptable. 
Microfluidics can be applied in the manufacturing of transferosomes using different 
techniques: electroformation, which consists on the hydration of a lipid film in the 
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presence of an alternating current (AC) electric field (Girard et al., 2004); pulsed jetting, 
which relies on a controlled pulsatile liquid jet directed into unilamellar lipid bilayer 
formed between two aqueous phases (Stachowiak et al., 2008); double emulsion transfer, 
which consists on the templating of the oil phase by the water droplets in this phase, and 
then transferring it to an aqueous phase by centrifugation or repeated washing; ice droplet 
hydration, which consists on a monodisperse W/O emulsion with an average droplet size 
prepared by microchannel emulsification. These droplets are frozen, separated and 
replaced by a surfactant and then the solvent is evaporated (Sugiura et al., 2008); 
hydrodynamic forces, which consist on a sample which is forced to pass through a small 
channel at a high flow speed (Golden et al., 2012). 
The formation of transferosomes is based on the diffusion of the different molecular 
species (usually alcohol and water, but also lipids) at the liquid interface between the 
solvent (alcohol) and the water. The alcohol diffuses into the aqueous phase until the 
solvent concentration decreases to a critical level, below the solubility limit of the lipids. 
This fact triggers the formation of the transferosomes by self-assembly. It is believed that 
the constant diffusion of alcohol and water across the interface leads to lipid precipitation, 
resulting in the formation of lipid vesicles. This technique has demonstrated a good 
uniformity in the production of particles as allows a direct control of their size by doing 
fine adjustments of the volumetric flow rate ratio between the lipid and aqueous phase or 





7. Transferosomes under clinical trials 
Several transferosomes are currently under clinical trials including drugs or 
phytocompounds as active pharmaceutical ingredients (API). 
Papaverine, a phytocompound obtained from Papaver somniferum known to produce 
relaxation of smooth muscles and dilation of blood vessels, is currently under clinical 
trials for the treatment of erectile dysfunction (Ali et al., 2015). The composition of this 
transferosomal formulation is soya phosphatidyl choline (50 mg), cholesterol (30 mg) and 
sodium deoxycholate, Span® 60 and Brij® 35 (polyoxyethylene lauryl ether) used as edge 
activators (25, 50 and 100 mg respectively) (Ali et al., 2015). 
A Phase I placebo-controlled study was performed including 9 men between 32 and 60 
years old from Minia University Hospital (Egypt) with at least 1-month history of erectile 
dysfunction. Participants received treatment with papaverine either encapsulated within 
transferosomes or mixed with hydroxypropyl methylcellulose (HPMC) hydrogel. The 
placebo group was treated with a HPMC hydrogel without the drug. The study took place 
during a 11-day period (Ali et al., 2015) that involved four sessions. During the 1st session 
(day 1), the hydrogel was applied. During the 2nd session (day 4): the hydrogel was 
applied again; biochemical and analytical measurements including blood pressure, heart 
rate, cavernous artery diameter and peak systolic flow were measured before and 1 hour 
after the administration of the gel. During the 3rd session (day 8): the application of 
hydrogel was also performed and erections were evaluated according to curvature of the 
penis. Finally, during the 4th session (day 11): penis and scrotum were evaluated to check 
any skin changes. 
The application of the transferosomal gel resulted in a 47 % statistically significant 
increase in the cavernous artery diameter. An increase in the diameter higher than 65 % 
happened in three of the volunteers treated with the transferosomal papaverine gel, but 
only in one patient treated with the free form gel. The application of the papaverine gels 
triggered a decrease in blood pressure in the hypertensive group and positive response to 
treatment appeared in 44 % of the volunteers. No undesirable effects were seen after the 
application of the gel; there was no evidence of skin irritation, erythematous rash, facial 
flushing, dizziness or pain in the area of application, ensuring the safety of the formulation 
(Ali et al., 2015). 
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8. Marketed transferosomes 
To the best of our knowledge, Diractin®, containing ketoprofen, has been the only 
transferosomal formulation to reach the market licensed by the Swiss Regulatory Agency 
(SwissMedic) in 2007. This formulation was indicated as a painkiller in knee 
osteoarthritis (Rother et al., 2009). Transferosomes were able to deliver ketoprofen to 
deeper tissues, including muscle, compared to conventional anti-inflammatory gels 
(Kneer et al., 2009). However, six months after the approval, the product was withdrawn 
by EMA as deemed only marginally superior efficacy compared to ketoprofen free-
vehicle (Kneer et al., 2013; Rajan et al., 2011). One of the main reasons that can explain 
the withdrawal from the market is the higher-cost associated with the manufacturing 
process of transferosomes compared to conventional gels. The higher manufacturing cost 
is linked with a greater medicine price. However, the marginal benefit obtained from the 
transferosomal formulation in terms of permeability is not enough to justify a higher 
treatment cost. When formulated appropiately, transferosomes have a greater 
permeability capacity than other topical dosage form and drug delivery systems. Its higher 
cost can be justified in certain diseases that require higher permeability into deeper 
tissues, even the bloodstream, or when formulating challenging molecules that possess 
extremely poor permeability properties. In those cases, the clinical benefit from using 
transferosomes would be greater and hence, the economic cost can be justified. 
Ketoprofen is a lipophilic drug (log P=3.61 (DrugBank, 2019)) with low molecular 
weight (254 g/mol). Hence, its permeability across the skin is acceptable and hence, a 
conventional gel delivers enough drug to elicit a pharmacological effect. For this reason, 
a transferosomal ketoprofen formulation was not ideal as the room for improvement was 
limited. 
9. Future perspectives and concluding remarks 
Lipid nano-carriers are highly researched and utilised technologies for transcutaneous and 
transdermal delivery across the stratum corneum. Transferosomes have shown to have an 
important advantage over liposomes and niosomes due to their ultra-deformable 
properties conferred by the edge activator that allows them to reach deeper layers inside 
the skin via intercellular and paracellular routes across the corneocytes. QbD can be 
utilised to guide the development of optimal transferosomal composition as well as the 
effect of manufacturing processing. Work is still needed in translating lab scale 
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manufacture of transferosomes to industrial processess ensuring that final products 
maintain their composition, stability, loading, and particle size. Clinical studies so far 
confirm the tolerability of the transferosomal formulations, however, work is still needed 
to develop protocols in combining this technology with other techniques used for 
permeation enhancement such as iontophoresis, electroporation and microneedles to 
facilitate further drug delivery of drugs across the skin (Prausnitz and Langer, 2008); 
although very few reports has been found in literature about the combination of these 
techniques with transferosomes, a synergistic effect on the skin permeability could be 
achieved bearing in mind their mechanism of action. In the case of iontophoresis, the 
increase in permeability is obtained by providing an electric driving force for transport 
the drug across the SC (Malakar et al., 2012). Small and hydrophilic drugs are the ideal 
candidates for this technique based on the principle that in a given electric field, cations 
(positively charged drugs) are repelled by a positive electrode called anode and are 
directed towards the catode, while anions (negatively charged molecules) follow the 
anode after being repelled by the negative electrode, catode (Karpinski, 2018). The 
combination of transferosomes and electroporation can be another viable option for 
increasing the skin permeation based on the formation of temporarily aqueous pores in 
cell membranes after the application of high voltage pulses (Ita, 2016). Even though, this 
technique has a broader application for different lipophilicites and sizes including high 
molecular weight biopharmaceuticals, the voltage applied could also disturbe the integrity 
of the transferosomes and hence, limiting their skin penetration. In the case of 
microneedles, the formation of micron-scale pathways into the skin, as well drive 
nanomedicines directly into the skin can potentially enhance the delivery of 
transferosomes across the SC (Wu et al., 2019; Yang et al., 2019). In this sense, the 
manufacturing of dissolvable microneedles containing transferosomes immobilised 
within a solid matrix could resolve the long term stability issues of the transferosomes in 
liquid media. In conclusion, there are plenty of options to explore in order to improve the 
capabilities of transferosomes and close the gap between lab-scale manufacturing and 
clinical medicines based on transferosomes. Apart from all the mentioned studies, 
transferosomes have been recently formulated to deliver proteins, such us the growth 
hormone (Azimi, 2019) or oligopeptides (Jiang et al., 2018).  
26 
 
10. Figure legends 
 
Figure 1. Schematic representation of the composition of a transferosome including 
the main components: hydrophilic and hydrophobic drugs, phospholipids and edge 









Figure 2. Schematic representation of the mechanism of penetration of 
transferosomes across the skin. After topical administration, the transferosome is 
exposed to a transdermal osmotic gradient due to the difference in water content 
between the stratum corneum and the viable epidermis. This gradient triggers the 
evaporation of the liquid of the transferosome and make favorable its deformation 
and penetration across the stratum corneum towards deeper and more aqueous 






Figure 3. Multilinear regression analysis (using Unscrambler®) of the compiled data 
illustrated in Table 1. The effect of the percentage of lipids and edge activator on the 
particle size, zeta-potential and in vitro permeability was evaluated. Those 
formulations containing an ionic edge activator (sodium deoxycholate) were 
analyzed separately from those formulated with a non-ionic surfactant (Tween® 80 
and Span® 80). Key: sodium deoxycholate used as edge activator (a, b and c); Span® 






Figure 4. A) Steps to follow in the QbD process of the manufacturing of 
transferosomes: including target product profile (TPP), critical quality attributes 
(CQAs), critical material attributes (CMAs), and critical process parameters 
(CPPs). B) Ishiwaka diagram representing the most critical parameters in the 







Figure 5. Application of QbD in the optimization of transferosomes. Key: A) 
Schematic representation of a ternary diagram. B) Constrained mixture design 
(contour plot) for optimization of particle size where the factors A, B, and C 
represent the amount of drug, lipid and edge activator in the transferosomal 
formulation. C) 3D surface plot exhibiting the relationship between the effect of the 







Figure 6. Schematic representation of lab and industrial scale techniques in the 
manufacturing of transferosomes, including thin film hydration method, sonication, 
extrusion, sequential filtration, homogenization, ethanol injection method, 

























Table 1. Summary of transferosomal formulations under preclinical research. The main components 
of the formulations are illustrated in the table: phospholipid, edge activator and drug. Key: DSPE: 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine; DC, sodium deoxycholate; PANAM G3, polyamido amide 
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Table 2. Preparation of transferosomes using QbD.  
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Table 3. Comparison among the different techniques employed in the preparation of 
transferosomes.  
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Easy to perform 
High drug encapsulation rates 
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